Tiziana Life SciencesLife Sciences has dosed the first patient in a randomized, placebo-controlled Phase 2 study of intranasal foralumab in early Alzheimer’s disease, evaluating the fully human anti-CD3 antibody as monotherapy and as an add-on to approved anti-amyloid agents lecanemab and donanemab. The trial’s endpoints center on neuroinflammation quantified by TSPO-PET, along with cognitive measures and changes in amyloid/tau biomarkers, with interim data expected in 2026.
The move formalizes Tiziana’s bet that residual neuroinflammation persists even after amyloid clearance and represents a tractable driver of progression in early disease. The design leans into that thesis: microglial activation is the imaging anchor, while combination cohorts test pragmatic positioning alongside the current standard for disease modification. Tiziana’s rationale is bolstered by TSPO-PET readouts indicating persistent microglial activation in anti-amyloid–treated patients and by prior signals of microglial modulation with intranasal foralumab in multiple sclerosis. However, the translatability of that signal to Alzheimer’s remains unproven.
Strategically, this is an expansion play aimed at creating an adjunctive neuroimmune pillar in Alzheimer’s, with a hedge on monotherapy to preserve optionality if combinations prove operationally or commercially constrained. Centering TSPO-PET allows the company to prosecute the mechanism quickly and potentially enrich responders. Still, it also introduces the familiar tension: imaging wins won’t carry late-stage programs without parallel cognitive and functional gains. The intranasal route is a differentiator on paper—immunomodulation without infusion burden—, but anti-CD3 remains a delicate class, and regulators will scrutinize durability, infection risk, and interactions with anti-amyloid regimens.
For sites and CROs, the protocol points to an imaging-heavy, coordination-intensive execution. TSPO-PET capability and radioligand supply will narrow site geography and increase startup complexity, elevating the role of imaging CROs and central reads. Combination arms will likely draw from patients already managed at infusion centers, requiring tight cross-site workflows for scheduling MRIs for ARIA monitoring, infusions, and PET scans. The intranasal regimen may reduce chair time, but additional imaging visits and biomarker sampling will raise patient burden and dropout risk. Sponsors and payers will watch for whether any TSPO-PET signal correlates with cognition and tau dynamics, which would strengthen the case for add-on reimbursement in a field already grappling with access, monitoring costs, and capacity constraints.
The broader context is a shift in the pipeline beyond amyloid toward microglia, complement, and innate immune targets. Foralumab enters this lane with a mechanistic lens and a practical read on real-world use—co-therapy with existing antibodies. What will matter next is enrollment velocity across PET-enabled centers, the magnitude and reproducibility of TSPO-PET changes, and whether cognitive readouts move in tandem. Safety will be closely watched, particularly immunosuppression signals and any additive risks when paired with lecanemab or donanemab. If the study reproduces an apparent reduction in neuroinflammation, with aligned biomarker and cognitive trends, Tiziana could justify a Phase 2b/3 path with clinical endpoints and begin conversations on combination development logistics and payer positioning. If signals bifurcate—imaging without cognition—the program may need to refine dosing, patient selection, or commit to an adjunct-only strategy. The near-term indicator to monitor is whether the trial can recruit and retain at pace within the constraints of the TSPO-PET infrastructure while generating data that bridges the mechanism to meaningful clinical effect.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
